NINTAI INVESTMENTS
  • About
  • Nintai Insights
  • Recommended Reading
  • Contact
  • Performance
  • Client Forms

A Purchase and a Sale at nintai

6/4/2015

0 Comments

 
Over the past several weeks, we’ve had several investment partners of Nintai question our decisions to purchase stocks with the markets at mostly all-time highs. It’s a reasonable question to ask and one we never get tired of answering. First, we believe that while markets are fairly priced at this stage, it’s important to understand every market is a sum of individual companies. Individual equities can – and probably will – trade at ranges quite distinct from market returns. We believe this makes for investment opportunities even though the markets may seem quite pricey. With that in mind, we made some changes to the Nintai Portfolio over the past few days including one sale and one new purchase.

BUY: Intuitive Surgical (ISRG)

We sold ISRG in 2012 after holding it for roughly 16 months after it ran away from us and reached a price far in excess of our estimated fair value. With 20/20 hindsight we made a relatively smart move for which we can take absolutely no credit. Since our sale, the stock returned roughly 14% versus the S&P 500 TR return of 65%. However, it should be noted we were right for the wrong reasons. In our calculations at the time we had free cash flow rising to roughly $700M by 2014. Looking at ISRG’s free cash flow, one might think we were slightly too optimistic in our projections.

Not shown in these numbers are two important decisions by ISRG management. First, was management’s decision that the company was undervalued after share price decreases in 2013 and 2014. The second was management’s decision to aggressively purchase roughly $2B in shares through the open market utilizing free cash during this period. Shares outstanding have decreased from 41.1M at year-end 2012 to 37.7M by year-end 2014. Taking that into account, free cash flow would have nearly doubled in the years 2013 and 2014 making the numbers starting in 2010 the following:

In essence, the company had generated roughly $1.6B in free cash in 2014 versus our estimate made in 2012 of $700M. Boy, did we get that wrong! When we factored in this new growth rate, we significantly increased our fair value of ISRG reflecting the value of cash and time.

This is simply one part of why we have purchased the stock. We also believe they have answered several questions we thought could greatly impact future growth. These included settlements with the FDA, clear market acceptance of robotic surgery in new therapeutic groups, and maintaining a clear dominance in the field. Utilizing our median growth model we believe the company is worth $532/share. Accordingly we added ISRG to the Nintai portfolio on Friday, May 29 at $486.34/share.

SELL: Cognizant Technology (CTSH)

Our decision to sell Cognizant is based on two reasons. First, Nintai believes the company’s base valuation is roughly $63/share. Currently trading at roughly $65/share, we would have been comfortable holding the company for the foreseeable future. Unfortunately, the company decided to take on $925M in long-term debt and $150M in short-term debt. While we completely understand the rationale for this move, this shaved roughly 6% off of our fair value estimate bringing it to roughly 10% above fair value. Combined with an internal negative financial strength rating, we believe there is simply too much risk for our investors and no reasonable case to make for an adequate return going forward. We like this space and if we could obtain a better price might have interest in Infosys (INFY) with its pristine balance sheet, high returns, and more compelling valuation.

Accordingly, we sold our entire position in CTSH on Monday, June 1 for an average price of $65.61. We first purchased the stock in November 2007 when we initiated our position at $9.11/share. Taking into account a 2:1 split in 2014, our total return was roughly 620%.

As always, we look forward to your thoughts and comments.

0 Comments



Leave a Reply.

    Author

    Mr. Macpherson is the Chief Investment Officer and Managing Director of Nintai Investments LLC. 

    Archives

    May 2025
    April 2025
    March 2025
    February 2025
    January 2025
    December 2024
    November 2024
    September 2024
    July 2024
    June 2024
    May 2024
    February 2024
    January 2024
    December 2023
    November 2023
    September 2023
    August 2023
    July 2023
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    December 2021
    October 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    July 2018
    June 2018
    May 2018
    March 2018
    February 2018
    December 2017
    September 2017
    August 2017
    June 2017
    May 2017
    April 2017
    March 2017
    January 2017
    December 2016
    November 2016
    October 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014

    Categories

    All

    RSS Feed

Proudly powered by Weebly